Reducing symptoms and improving daily life are related goals, but they are not the same outcome. A historical lisdexamfetamine trial measured parents’ perceptions of achievement, comfort and functioning separately from the main ADHD symptom assessment.
The randomized comparison
Banaschewski and colleagues analyzed secondary outcomes from a seven-week trial in participants aged 6–17. The study randomized 336 children and adolescents to once-daily oral lisdexamfetamine, placebo or osmotic-release methylphenidate. Lisdexamfetamine doses were optimized at 30, 50 or 70 mg/day; the reference methylphenidate doses were 18, 36 or 54 mg/day.
The full analysis set contained 317 participants: 104 receiving lisdexamfetamine, 106 placebo and 107 methylphenidate. Among this set, 77, 42 and 72 completed the study, respectively. Thus endpoint analyses were not simply a comparison of 317 complete seven-week records.
What did parents rate?
The CHIP-CE parent form measured health-related quality of life. Achievement was the prespecified primary quality-of-life domain. The WFIRS-P assessed functional difficulties in domains including family, school, life skills and social activities.
These were parent-reported scales. Achievement ratings are not independent school transcripts, and a scale labeled risk avoidance is not a road-driving experiment. Each outcome retains the meaning of its questionnaire.
The positive and null findings
Lisdexamfetamine improved the Achievement domain versus placebo, with a reported standardized effect size of 1.280. Risk Avoidance, Resilience and Satisfaction also improved significantly. Comfort did not show a significant placebo-adjusted improvement.
On functional impairment, significant effects were likewise not uniform across domains. For example, the Life Skills comparison did not reach significance for lisdexamfetamine. This prevents summarizing the trial as improvement in every aspect of life.
An effect size is a standardized group difference. It is not the proportion of children whose functioning became normal or the probability of benefit for one patient.
Why comparator and endpoint matter
Methylphenidate served as a reference treatment. Separate comparisons of each medicine with placebo do not establish a statistically tested difference between the active medicines.
Endpoint used the last on-treatment visit with valid data, potentially including early termination. Differential discontinuation, especially for lack of efficacy in placebo recipients, complicates interpretation. Seven weeks also leaves uncertainty about sustained functional change.
What can reasonably be concluded?
This industry-sponsored trial provides randomized evidence for selected parent-rated benefits in a defined ADHD population. It does not validate a general claim that amphetamine improves every person’s functioning, establish driving safety or separate every expectation-related influence on parent ratings. This is a secondary analysis of the original trial, not an independent replication.
Scientific source
Banaschewski T, Soutullo C, Lecendreux M, et al. Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder. CNS Drugs. 2013;27:829–840. doi:10.1007/s40263-013-0095-5. Original commentary on the supplied paper.
Leave a Reply